MediWound Ltd.
Business
MediWound Ltd. is a biopharmaceutical company that develops and commercializes proteolytic enzyme–based therapies for non‑surgical tissue repair. Its principal products and pipeline include NexoBrid (enzymatic eschar removal for deep burns), EscharEx (enzymatic debridement for chronic and hard‑to‑heal wounds) and MW005 (topical therapy for basal cell carcinoma), supported by in‑house R&D and sterile cGMP manufacturing. The company organizes activities across burn care, chronic wound care and oncology pipeline programs, plus manufacturing and strategic collaborations. It commercializes products in over 40 countries, selling directly in Europe and Israel, via an exclusive North American licensee, and through local distributors across Asia‑Pacific, the Middle East and other international markets.
Summary from filing dated 2025-03-19
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-23.88M |
| Total assets | $86.25M |
| Total liabilities | $42.62M |
| Stockholders' equity | — |
| Operating cash flow | — |